Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $10.3 million.

  • Addex Therapeutics' Liabilities and Shareholders Equity fell 32.17% to $10.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $47.1 million, marking a year-over-year increase of 51.07%. This contributed to the annual value of $12.1 million for FY2024, which is 134.85% up from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Liabilities and Shareholders Equity is $10.3 million, which was down 2.61% from $10.5 million recorded in Q1 2025.
  • Addex Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $19.1 million for Q1 2022, and its period low was $3.8 million during Q1 2024.
  • In the last 3 years, Addex Therapeutics' Liabilities and Shareholders Equity had a median value of $10.1 million in 2025 and averaged $9.6 million.
  • As far as peak fluctuations go, Addex Therapeutics' Liabilities and Shareholders Equity plummeted by 58.81% in 2023, and later soared by 176.01% in 2025.
  • Over the past 4 years, Addex Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $8.6 million in 2022, then slumped by 39.13% to $5.2 million in 2023, then spiked by 132.93% to $12.2 million in 2024, then plummeted by 32.17% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q2 2025, $10.5 million for Q1 2025, and $12.2 million during Q4 2024.